Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (391-400 of 418) with videos related to

Pageof 42
Sort By:
Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.
Science Translational Medicine|February 18, 2021
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responsesJennifer A Lo, Masayoshi Kawakubo, Vikram R Juneja, et al.
Journal of the National Cancer Institute|January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial DesignKeith T Flaherty, Robert Gray, Alice Chen, et al.
Science (New York, N.Y.)|April 29, 2016
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seqItay Tirosh, Benjamin Izar, Sanjay M Prakadan, et al.
The Journal of Clinical Investigation|April 5, 2016
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitorsGao Zhang, Dennie T Frederick, Lawrence Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
The State of Melanoma: Emergent Challenges and OpportunitiesMichael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, et al.
Science Advances|November 27, 2024
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaGiuseppe Tarantino, Cora A Ricker, Annette Wang, et al.
Pigment Cell & Melanoma Research|April 19, 2016
The state of melanoma: challenges and opportunitiesGlenn Merlino, Meenhard Herlyn, David E Fisher, et al.
Cell Reports. Medicine|March 4, 2022
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSamuel S Freeman, Moshe Sade-Feldman, Jaegil Kim, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Pageof 42

Showing results (391-400 of 418) with videos related to

Sort By:
Pageof 42
Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.
Science Translational Medicine|February 18, 2021
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responsesJennifer A Lo, Masayoshi Kawakubo, Vikram R Juneja, et al.
Journal of the National Cancer Institute|January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial DesignKeith T Flaherty, Robert Gray, Alice Chen, et al.
Science (New York, N.Y.)|April 29, 2016
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seqItay Tirosh, Benjamin Izar, Sanjay M Prakadan, et al.
The Journal of Clinical Investigation|April 5, 2016
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitorsGao Zhang, Dennie T Frederick, Lawrence Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
The State of Melanoma: Emergent Challenges and OpportunitiesMichael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, et al.
Science Advances|November 27, 2024
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaGiuseppe Tarantino, Cora A Ricker, Annette Wang, et al.
Pigment Cell & Melanoma Research|April 19, 2016
The state of melanoma: challenges and opportunitiesGlenn Merlino, Meenhard Herlyn, David E Fisher, et al.
Cell Reports. Medicine|March 4, 2022
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSamuel S Freeman, Moshe Sade-Feldman, Jaegil Kim, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Pageof 42